A candidate gene study of capecitabine-related toxicity in colorectal cancer identifies new toxicity variants at DPYD and a putative role for ENOSF1 rather than TYMS

Gut

Volumn 64, Issue 1, 2015, Pages 111-120

  Rosmarin, Dan ^a,b   Palles, Claire ^a   Pagnamenta, Alistair ^c   Kaur, Kulvinder ^c   Pita, Guillermo ^d   Martin, Miguel ^e   Domingo, Enric ^a,c   Jones, Angela ^a   Howarth, Kimberley ^a   Freeman Mills, Luke ^a   Johnstone, Elaine ^b   Wang, Haitao ^b   Love, Sharon ^b   Scudder, Claire ^f   Julier, Patrick ^f   Fernández Rozadilla, Ceres ^a   Ruiz Ponte, Clara ^g   Carracedo, Angel ^g   Castellvi Bel, Sergi ^h   Castells, Antoni ⁱ   Gonzalez Neira, Anna ^d   Taylor, Jenny ^c   Kerr, Rachel ^b   Kerr, David ^b   Tomlinson, Ian ^a,c   more..

^a Molecular and Population Genetics Laboratory   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d Structural Biology and Biocomputing Programme   (Spain)

^e UNIVERSIDAD COMPLUTENSE DE MADRID   (Spain)

^f UNIVERSITY OF OXFORD   (United Kingdom)

^g CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^h INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

ⁱ HOSPITAL CLÍNIC   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; DIHYDROPYRIMIDINE DEHYDROGENASE; MESSENGER RNA; THYMIDYLATE SYNTHASE; ANTINEOPLASTIC ANTIMETABOLITE; DEOXYCYTIDINE; FLUOROURACIL; PROTEIN; RTS PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DIARRHEA; DIHYDROPYRIMIDINE DEHYDROGENASE GENE; DISEASE SEVERITY; ENOSF1 GENE; FEMALE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE IDENTIFICATION; GENE LOCUS; GENETIC ASSOCIATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; GENOTYPE; HAND FOOT SYNDROME; HUMAN; INTRON; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; NEUTROPENIA; PHARMACOGENETICS; SINGLE NUCLEOTIDE POLYMORPHISM; STOMATITIS; THROMBOCYTOPENIA; THYMIDYLATE SYNTHASE GENE; UNITED KINGDOM; VERY ELDERLY; VOMITING; ANALOGS AND DERIVATIVES; COLORECTAL NEOPLASMS; GENETIC POLYMORPHISM; GENETICS; MIDDLE AGED; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; CAPECITABINE; COLORECTAL NEOPLASMS; DEOXYCYTIDINE; DIHYDROURACIL DEHYDROGENASE (NADP); FEMALE; FLUOROURACIL; GENETIC ASSOCIATION STUDIES; HUMANS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PROTEINS; THYMIDYLATE SYNTHASE; YOUNG ADULT;

EID: 84919781447     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2013-306571     Document Type: Article

References (25)

1. Noordhuis P, Holwerda U, Van Laar JA, et al. A non-radioactive sensitive assay to measure 5-fluorouracil incorporation into DNA of solid tumors. Nucleosides Nucleotides Nucleic Acids 2004; 23: 1481-4.
2. Saltz LB, Niedzwiecki D, Hollis D, et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-61.
3. Cassidy J, Twelves C, Van Cutsem E, et al. First-line oral capecitabine therapy in metastatic colorectal cancer: a favorable safety profile compared with intravenous 5-fluorouracil/leucovorin. Ann Oncol 2002; 13: 566-75.
4. Haller DG, Rothenberg ML, Wong AO, et al. Oxaliplatin plus irinotecan compared with irinotecan alone as second-line treatment after single-agent fluoropyrimidine therapy for metastatic colorectal carcinoma. J Clin Oncol 2008; 26: 4544-50.
5. Stein BN, Petrelli NJ, Douglass HO, et al. Age and sex are independent predictors of 5-fluorouracil toxicity. Analysis of a large scale phase III trial. Cancer 1995; 75: 11-7.
6. Thorn CF, Marsh S, Carrillo MW, et al. PharmGKB summary: fluoropyrimidine pathways. Pharmacogenet Genomics 2011; 21: 237-42.
7. Rosmarin D, Rosmarin D, Palles C, et al. Genetic markers of toxicity from capecitabine and other 5-fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review and meta-analysisGenetic markers of toxicity from capecitabine and other 5-fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review and meta-analysis. J Clin Oncol Published Online First: 3 Mar 2014. doi: 10.1200/JCO.2013.51.1857
8. Caudle KE, Thorn CF, Klein TE, et al. Clinical pharmacogenetics implementation consortium guidelines for dihydropyrimidine dehydrogenase genotype and fluoropyrimidine dosing. Clin Pharmacol Ther 2013; 94: 640-5.
9. Dunlop MG, Dobbins SE, Farrington SM, et al. Common variation near CDKN1A, POLD3 and SHROOM2 influences colorectal cancer risk. Nat Genet 2012; 44: 770-6.
10. Huyghe JR, Jackson AU, Fogarty MP, et al. Exome array analysis identifies new loci and low-frequency variants influencing insulin processing and secretion. Nat Genet 2013; 45: 197-201.
11. Goldstein JI, Crenshaw A, Carey J, et al. zCall: a rare variant caller for array-based genotyping: genetics and population analysis. Bioinformatics (Oxford, England) 2012; 28: 2543-5.
12. Howie B, Fuchsberger C, Stephens M, et al. Fast and accurate genotype imputation in genome-wide association studies through pre-phasing. Nat Genet 2012; 44: 955-9.
13. Delaneau O, Howie B, Cox AJ, et al. Haplotype estimation using sequencing reads. Am J Hum Genet 2013; 93: 687-96.
14. Marchini J, Howie B, Myers S, et al. A new multipoint method for genome-wide association studies by imputation of genotypes. Nat Genet 2007; 39: 906-13.
15. Dotor E, Cuatrecases M, Martinez-Iniesta M, et al. Tumor thymidylate synthase 1494del6 genotype as a prognostic factor in colorectal cancer patients receiving fluorouracil-based adjuvant treatment. J Clin Oncol 2006; 24: 1603-11.
16. Horie N, Aiba H, Oguro K, et al. Functional analysis and DNA polymorphism of the tandemly repeated sequences in the 5'-terminal regulatory region of the human gene for thymidylate synthase. Cell Struct Funct 1995; 20: 191-7.
17. Cuppen E. Genotyping by Allele-Specific Amplification (KASPar). CSH protocols 2007; 2007: pdb prot4841. doi: 10.1101/pdb.prot4841 [published Online First: Epub Date]
18. Nica AC, Parts L, Glass D, et al. The architecture of gene regulatory variation across multiple human tissues: the MuTHER study. PLoS Genet 2011; 7:e1002003.
19. Dimas AS, Deutsch S, Stranger BE, et al. Common regulatory variation impacts gene expression in a cell type-dependent manner. Science (New York, NY) 2009; 325: 1246-50.
20. Stranger BE, Montgomery SB, Dimas AS, et al. Patterns of cis regulatory variation in diverse human populations. PLoS Genet 2012; 8:e1002639.
21. Dolnick BJ, Angelino NJ, Dolnick R, et al. A novel function for the rTS gene. Cancer Biol Ther 2003; 2: 364-9.
22. Lecomte T, Ferraz JM, Zinzindohoue F, et al. Thymidylate synthase gene polymorphism predicts toxicity in colorectal cancer patients receiving 5-fluorouracil-based chemotherapy. Clin Cancer Res 2004; 10: 5880-8.
23. Schwab M, Zanger UM, Marx C, et al. Role of genetic and nongenetic factors for fluorouracil treatment-related severe toxicity: a prospective clinical trial by the German 5-FU Toxicity Study Group. J Clin Oncol 2008; 26: 2131-8.
24. Van Kuilenburg AB, Meinsma R, Beke E, et al. Identification of three novel mutations in the dihydropyrimidine dehydrogenase gene associated with altered pre-mRNA splicing or protein function. Biol Chem 2005; 386: 319-24.
25. Ghosh S, Winter JM, Patel K, et al. Reexamining a proposal: thymidylate synthase 5'-untranslated region as a regulator of translation efficiency. Cancer Biol Ther 2011; 12: 750-5.